A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).
暂无分享,去创建一个
M. Minden | Z. Estrov | H. Kantarjian | G. Garcia-Manero | S. Verstovsek | R. Martell | J. Fiorentino | G. Reid